West Announces First-Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
West Pharma (WST) Tops Q1 EPS by 19c, Revenues Beat; Raises FY20 EPS Guidance Above Consensus, FY20 Revenue Outlook Above Consensus
April 23, 2020 6:11 AM EDTWest Pharma (NYSE: WST) reported Q1 EPS of $1.01, $0.19 better than the analyst estimate of $0.82. Revenue for the quarter came in at $491.5 million versus the consensus estimate of $466.79 million.
First-Quarter 2020 Summary (comparisons to prior-year period)
Net sales of $491.5 million grew 10.8%; organic sales growth was 12.7%.
Reported-diluted EPS of $0.99 increased 36%.
Adjusted-diluted EPS of $1.01 increased 36%.
The Company is maintaining full-year 2020 net sales guidance and is updating full-year 2020 adjusted-diluted EPS guidance to a new range of $3.52 to $3.62, compared to a prior range of $3.45 to $3.55.
"Adjusted-diluted EPS" and "organic sales growth" are Non-U.S. GAAP... More
